US 9212212
Targeting complement factor H for treatment of diseases
granted A61KA61K38/00A61P
Quick answer
US patent 9212212 (Targeting complement factor H for treatment of diseases) held by The Regents of the University of Colorado, a Body Corporate expires Mon Dec 10 2035 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.
Key facts
- Applicant
- The Regents of the University of Colorado, a Body Corporate
- Grant date
- Tue Dec 15 2015 00:00:00 GMT+0000 (Coordinated Universal Time)
- Expiration
- Mon Dec 10 2035 00:00:00 GMT+0000 (Coordinated Universal Time)
- Claims
- 13
- CPC classes
- A61K, A61K38/00, A61P, A61P1/04, A61P11/06